Printer Friendly

39. Randomized and non-randomized controlled cohort studies for the prevention of cancer with a mistletoe extract for myomas, endometrioses and cervix dysplasia.

Aim: Long-term comparative study of the preventive effect of therapy with Iscador[R] mistletoe extract, as complementary treatment to standard therapy, on the incidence of cancer and survival in female patients suffering from myomas, endometrioses or cervix dysplasia.

Design: A matched-pair study design involving, respectively, one randomized and one non-randomized controlled prospective cohort study on female patients with myomas, endometrioses and cervix dysplasia. The matching criteria encompass diagnosis parameters, age at first diagnosis and year of first diagnosis.

Setting: Recruitment of subjects from: the Heidelberg Prospective Intervention Study, six hospital and after-care institutions in Germany, and the Institute for Preventive Medicine in Heidelberg.

Study duration: Prospective data recording between 1973 and 1998. Concluding follow-up from 1999 to 2001.

Patients: Female patients with myomas (subserous, submucous, intramural), endometrioses or cervix dysplasia (PAP III and IV).

Tested medication: Iscador[R] mistletoe preparation as complementary therapy to standard treatment.

Target criteria: Cancer incidence, tumour-related survival and overall survival.

Results: In the randomized studies, the Iscador group of patients with endometrioses and cervix dysplasia showed significantly lower incidence of cancer and a tendency to longer tumour-related survival periods; in the case of myomas no significant effects were found. In the non-randomized studies there was significantly lower incidence of cancer and significantly longer tumour-related survival in Iscador patients with myomas and endometrioses; no effects were found for cervix dysplasia.

Conclusions: For endometrioses, the randomized and non-randomized study demonstrated consistently positive effects on cancer incidence and tumour-related survival in the Iscador group. For cervix dysplasia the positive effects in the randomized study were not confirmed by the non-randomized study. No effect on overall survival was found. In the case of endometrioses, in particular, mistletoe therapy may have a positive influence on incidence of cancer and tumour-related survival.

Keywords: Viscum album L.; Iscador; Cancer incidence; Survival; Endometriosis; Myoma; Cervix dyplasia

R. Ziegler (a,*), R. Grossarth-Maticek (b)

(a) Hiscia Institute, Verein fur Krebsforschung, 4144 Arlesheim, Switzerland

(b) Institute for Preventive Medicine, European Center for Peace and Development (ECPD), 67117 Heidelberg, Germany

*Corresponding author. Tel.: +41 61 706 72 45; fax: +41 61 706 72 00.

E-mail address: (R. Ziegler).
COPYRIGHT 2007 Urban & Fischer Verlag
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ziegler, R.; Grossarth-Maticek, R.
Publication:Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
Geographic Code:4EXSI
Date:Oct 1, 2007
Previous Article:38. Treatment with a fermented mistletoe (Viscum album L.) extract as part of long-term supportive care in patients with primary non-metastatic...
Next Article:40. Self-cleavage of mistletoe lectin I into the A and B subunits by thiol-disulfide exchange reaction.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |